Ingrid Zhang is taking the helm of the cancer therapy company, filling a post vacant since its previous CEO abruptly resigned in July.

Sept 15 (Reuters) - Legend Biotech on Tuesday appointed longtime Novartis executive Ingrid Zhang as its CEO, effective immediately, banking on an industry veteran to steer its expansion beyond ...

The FDA has approved the industry’s very first generic radioligand therapy, known as a radioligand equivalent.  | The FDA has approved the industry’s first radioligand equivalent in Curium’s lutetium ...

Shares of Novartis tanked on Tuesday after results from its del-desiran drug trial disappointed investors.

Shares of Novartis fell more than 3% on Monday after its cholesterol drug failed in a closely watched study, dealing ‌a blow ...

The HARBOR study failure is Novartis's second major late-stage trial setback in days and its third pipeline blow in a week ...

Novartis’ shares fell 13% this week after the report of three separate late-stage asset failures. The impact went beyond the ...

Novartis suffered its third clinical-trial setback in a week after del-desiran, a treatment for a rare muscle-wasting disease ...

The stock fell about 10% following the announcement and has now lost more than 14% over the past five trading sessions. The failed drug, del-desiran, was being tested against myotonic dystrophy type 1 ...

The company said the late-stage study for its pelacarsen drug missed its primary objective of reducing the risk of ...

Back-to-back failures of multiple late-phase trials have raised questions about how Novartis has deployed capital in pursuit ...

The failure of a neuromuscular treatment is a blow to the drugmaker’s efforts to revive its growth prospects.